CN113150030A - 氧杂二环庚烷前药 - Google Patents

氧杂二环庚烷前药 Download PDF

Info

Publication number
CN113150030A
CN113150030A CN202110080437.0A CN202110080437A CN113150030A CN 113150030 A CN113150030 A CN 113150030A CN 202110080437 A CN202110080437 A CN 202110080437A CN 113150030 A CN113150030 A CN 113150030A
Authority
CN
China
Prior art keywords
alkyl
alkenyl
aryl
alkynyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110080437.0A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·S·科瓦奇
罗伯特·福尔克曼
安东尼·玛法特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lixte Biotechnology Inc
Original Assignee
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lixte Biotechnology Inc filed Critical Lixte Biotechnology Inc
Publication of CN113150030A publication Critical patent/CN113150030A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202110080437.0A 2015-05-15 2016-05-12 氧杂二环庚烷前药 Pending CN113150030A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562162501P 2015-05-15 2015-05-15
US62/162,501 2015-05-15
CN201680032555.1A CN107708686B (zh) 2015-05-15 2016-05-12 氧杂二环庚烷前药

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680032555.1A Division CN107708686B (zh) 2015-05-15 2016-05-12 氧杂二环庚烷前药

Publications (1)

Publication Number Publication Date
CN113150030A true CN113150030A (zh) 2021-07-23

Family

ID=57276640

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680032555.1A Expired - Fee Related CN107708686B (zh) 2015-05-15 2016-05-12 氧杂二环庚烷前药
CN202110080437.0A Pending CN113150030A (zh) 2015-05-15 2016-05-12 氧杂二环庚烷前药

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680032555.1A Expired - Fee Related CN107708686B (zh) 2015-05-15 2016-05-12 氧杂二环庚烷前药

Country Status (12)

Country Link
US (5) US9988394B2 (enExample)
EP (2) EP3294287B1 (enExample)
JP (3) JP7187023B6 (enExample)
CN (2) CN107708686B (enExample)
AU (1) AU2016263079B2 (enExample)
DK (1) DK3294287T3 (enExample)
ES (2) ES2795950T3 (enExample)
HU (1) HUE050177T2 (enExample)
IL (2) IL255516B (enExample)
MX (2) MX393461B (enExample)
TW (2) TWI757720B (enExample)
WO (1) WO2016186963A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013282365A1 (en) 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
BR112015025852A2 (pt) 2013-04-09 2017-07-25 Lixte Biotechnology Inc as formulações de oxabicicloheptanos e oxabicicloheptenos
WO2016014783A1 (en) 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CA2977256C (en) 2015-02-19 2023-08-08 John S. Kovach Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
ES2795950T3 (es) 2015-05-15 2020-11-25 Lixte Biotechnology Inc Profármacos de oxabicicloheptano
US12168008B2 (en) 2016-12-08 2024-12-17 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103788108A (zh) * 2007-02-06 2014-05-14 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
CN104619710A (zh) * 2012-06-29 2015-05-13 里克思特生物技术有限公司 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
US6949624B1 (en) 1999-08-03 2005-09-27 The United States Of America As Represented By The Department Of Health And Human Services Cloning of the human nuclear receptor co-repressor gene
AU2001243253A1 (en) 2000-02-24 2001-09-03 Biocryst Pharmaceuticals, Inc. Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
WO2003045898A1 (en) 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
EP1986619A4 (en) 2006-02-06 2010-04-28 Lixte Biotechnology Inc USE OF PHOSPHATASES FOR THE TREATMENT OF TUMORS BY N-COR OVEREXPRESSION
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
US20080267947A1 (en) 2006-09-07 2008-10-30 Cirrito Thomas P Cancer therapy with cantharidin and cantharidin analogs
US20080097561A1 (en) 2006-10-18 2008-04-24 Medcool, Inc. Dual cycle thermal system and method of use
WO2008058342A1 (en) * 2006-11-15 2008-05-22 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
EP2185173A4 (en) * 2007-08-03 2011-01-12 Lixte Biotechnology Inc USE OF PHOSPHATASES FOR THE TREATMENT OF NEUROBLASTOMES AND MEDULLOGASTOMES
MX2010003417A (es) 2007-10-01 2010-09-10 Lixte Biotechnology Inc Inhibidores de histona desacetilasa.
EP2309853A4 (en) 2008-08-01 2012-04-25 Lixte Biotechnology Inc METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
AU2009277086B2 (en) 2008-08-01 2015-12-10 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
MX2012012225A (es) 2010-04-23 2013-08-27 Piramal Entpr Ltd Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
CA2836940A1 (en) * 2011-05-24 2012-11-29 Lixte Biotechnology, Inc. Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
BR112014029478B1 (pt) 2012-06-01 2023-01-17 Taisho Pharmaceutical Co., Ltd Compostos, fármacos de aminoácido contendo flúor e uso destes
AU2013282365A1 (en) * 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
US20160008336A1 (en) 2013-03-05 2016-01-14 Lixte Biotechnology, Inc. Hdac inhibitors for the treatment of traumatic brain injury
US20160009727A1 (en) 2013-03-15 2016-01-14 Lixte Biotechnology, Inc. Sanguinarine analog pp2c inhibitors for cancer treatment
BR112015025852A2 (pt) 2013-04-09 2017-07-25 Lixte Biotechnology Inc as formulações de oxabicicloheptanos e oxabicicloheptenos
EP3068398A4 (en) * 2013-11-15 2017-11-15 Lixte Biotechnology, Inc. Protein phosphatase inhibitors that cross the blood brain barrier
US9051332B1 (en) 2013-11-20 2015-06-09 Transitions Optical, Inc. Photochromic indeno-fused ring pyran compounds
EP3157336A4 (en) 2014-06-20 2018-01-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
WO2016014783A1 (en) 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
EP3191096A4 (en) * 2014-09-12 2018-03-21 Lixte Biotechnology, Inc. Human dosing of phosphatase inhibitor
US9994584B2 (en) * 2014-10-15 2018-06-12 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
CA2977256C (en) 2015-02-19 2023-08-08 John S. Kovach Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
ES2795950T3 (es) * 2015-05-15 2020-11-25 Lixte Biotechnology Inc Profármacos de oxabicicloheptano
US20190111053A1 (en) 2016-01-27 2019-04-18 Lixte Biotechnology, Inc. Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
US12168008B2 (en) 2016-12-08 2024-12-17 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US20210275521A1 (en) 2017-12-05 2021-09-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for treatment of secondary acute myeloid leukemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103788108A (zh) * 2007-02-06 2014-05-14 利克斯特生物技术公司 氧杂双环庚烷和氧杂双环庚烯，它们的制备及用途
CN104619710A (zh) * 2012-06-29 2015-05-13 里克思特生物技术有限公司 用于治疗再灌注损伤的氧杂二环庚烷和氧杂二环庚烯

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JARKKO RAUTIOET AL.: "Prodrugs: design and clinical applications", 《NATURE REVIEW DRUG DISCOVERY》, vol. 7, pages 255 - 270, XP055227338, DOI: 10.1038/nrd2468 *

Also Published As

Publication number Publication date
EP3294287B1 (en) 2020-04-08
TW202043237A (zh) 2020-12-01
TWI757720B (zh) 2022-03-11
US20190359627A1 (en) 2019-11-28
MX2017014549A (es) 2018-09-11
MX2021012440A (es) 2022-06-28
HUE050177T2 (hu) 2020-11-30
IL255516A (en) 2018-01-31
EP3294287A4 (en) 2018-10-31
EP3736275B1 (en) 2024-07-03
CN107708686A (zh) 2018-02-16
ES2795950T3 (es) 2020-11-25
US10364252B2 (en) 2019-07-30
US11236102B2 (en) 2022-02-01
EP3736275C0 (en) 2024-07-03
IL272027B (en) 2021-10-31
US20180244690A1 (en) 2018-08-30
EP3736275A1 (en) 2020-11-11
AU2016263079A1 (en) 2017-12-07
CA2986104A1 (en) 2016-11-24
JP2020180130A (ja) 2020-11-05
MX393461B (es) 2025-03-24
US20200325151A1 (en) 2020-10-15
ES2985668T3 (es) 2024-11-06
CN107708686B (zh) 2021-02-19
JP2023100645A (ja) 2023-07-19
JP2018515614A (ja) 2018-06-14
WO2016186963A1 (en) 2016-11-24
US20220235066A1 (en) 2022-07-28
HK1247576A1 (en) 2018-09-28
US11866444B2 (en) 2024-01-09
US10618908B2 (en) 2020-04-14
MX386975B (es) 2025-03-19
IL272027A (en) 2020-02-27
TW201713667A (zh) 2017-04-16
US20160333024A1 (en) 2016-11-17
US9988394B2 (en) 2018-06-05
AU2016263079B2 (en) 2019-08-15
TWI693226B (zh) 2020-05-11
IL255516B (en) 2020-02-27
JP7187023B2 (ja) 2022-12-12
JP7187023B6 (ja) 2023-01-05
EP3294287A1 (en) 2018-03-21
DK3294287T3 (da) 2020-06-08

Similar Documents

Publication Publication Date Title
CN107708686B (zh) 氧杂二环庚烷前药
US20160264593A1 (en) Protein phosphatase inhibitors that cross the blood brain barrier
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
JP2014510119A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン塩類
JP2015522032A (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
AU2017283653A1 (en) Porphyrin compounds and compositions useful for treating cancer
KR20230117574A (ko) 암 치료를 위한 metap2 억제제 및 cdk4/6 억제제의 조합
HK40041072A (en) Oxabicycloheptane prodrugs for use in treating cancer
CA2986104C (en) Oxabicycloheptane prodrugs
HK1247576B (en) Oxabicycloheptane prodrugs
EP4514354A1 (en) Compounds for proliferative disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723

WD01 Invention patent application deemed withdrawn after publication